Alaterre E, Vikova V, Kassambara A, Bruyer A, Robert N, Requirand G, Bret C, Herbaux C, Vincent L, Cartron G, Elemento O, Moreaux J. RNA-Sequencing-Based Transcriptomic Score with Prognostic and Theranostic Values in Multiple Myeloma. Journal of Personalized Medicine. 2021. Download the PDF
Summary of the Study
This study leverages RNA-sequencing data to develop a gene expression–based risk score that stratifies prognosis and predicts treatment sensitivity in multiple myeloma (MM).
A 267-gene score was constructed and validated across two independent cohorts:
- n = 674 (MMRF CoMMpass)
- n = 76 (external validation)
High-risk patients showed enrichment of gene signatures related to:
- Interferon response, IL-6 signaling
- MYC activation, cell proliferation
- Hypoxia, stemness, and epigenetic deregulation
The score was also correlated with somatic mutation profiles
Theranostic insights: response stratification for EZH2, MELK, TOPK/PBK, and Aurora kinase inhibitors
In this study, Alboukadel Kassambara contributed to the data analysis and visualization, supporting the development, validation, and interpretability of the RNA-seq–based transcriptomic score in multiple myeloma.
Citation
Publication: In Journal of Personalized Medicine
Date: September 30, 2021
Type: Journal Article
PDF: Download the PDF
Scientific Contributions
Here are more scientific abstracts authored or co-authored by Alboukadel Kassambara. These contributions span computational biology, bioinformatics, biostatistics, machine learning, and multi-omics, with a focus on immuno-oncology and translational research.
